Rowan Paul: MSCs Show Strongest Pain Reduction in Regenerative Medicine Approaches
Rowan Paul, Sports Medicine and Interventional Regenerative Orthobiologics Physician at RegenCore, shared on LinkedIn:
”My key takeaway is that MSCs showed the strongest pain reduction. Nice to see this born out in the peer reviewed literature. Happy to be doing Prospective Clinical Trial research.
PRP
Efficacy:
- Best for acute injuries and tendon repair-patellar tendinopathy, knee OA, lateral epicondylitis
- Superior to corticosteroids and HA
- Limited success in chronic conditions:
Limitations
- Hard to generalize across all indications. be precise in formulation of your PRP depending on structure, patient, and goals
- Inconsistent preparation methods
- Optimal: LP- PRP, weekly × 3 weeks
- Requires 10-12 billion cumulative over course:
Mechanism
- VEGF, PDGF, TGF-β release stimulates angiogenesis and matrix synthesis[1]
Mesenchymal Stem Cells (MSCs)
Efficacy:
- Highest pain reduction among all modalities
- Cartilage regeneration in early OA
- Sustained improvements at 12-24 months
Mechanism
- Immunomodulation, reduced inflammation, M2 macrophage polarization
Major Barriers:
- High costs and ethical concerns
- Experimental
- Symptomatic relief insufficient to justify costs on a system level
Peptide-Based Therapies
- Moderate improvements; promising for infection control and wound healing
- Limited evidence (10 studies)
- Needs optimization of dosing, delivery, safety
Biomimetic Materials
- Scaffolds, Autologous Protein Solutions, PRF.
- Lowest efficacy in meta-analysis[1]
Clinical Practice Insights
Standardization Challenges:
- Variable methods and heterogeneous formulations= inconsistent results
- Insufficient reporting limits evidence synthesis
- This is a particular interest of mine and we need more research
Evidence Characterization:
- ‘Symptom-modifying’ vs ‘structure-modifying’—improve pain/function but limited true regeneration
- Short/mid-term results noticeable; long-term stability undetermined
- Need long-term follow-up to see structural changes
Precision Medicine Need:
- Must identify potency markers to match treatments to tissues/pathologies
- Improved mechanistic understanding enables precision approaches
Market Landscape
- 51.5% of publications focus on PRP, 30.8% bone marrow, 15.2% adipose-derived cells. We need more MSC research as well as scaffolding research and this takes investment and funding.”
Title: Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications
Authors: Andrew J Goulian, Brielle Goldstein, Maarouf A Saad
Read the Full Article on National Library of Medicine.

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support